CANACCORD GENUITY MUSCULOSKELETAL CONFERENCE 2023 MARCH 7, 2023 ANIKA. RESTORE ACTIVE LIVING.™ SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorpor ...

Q4 AND YEAR-END 2022 EARNINGS CALL MARCH 6, 2023 ANIKA. RESTORE ACTIVE LIVING.™ SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking statements wit ...

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2022 Earnings Conference Call March 6, 2023 5:00 PM ET Company Participants Mark Namaroff - VP, IR, ESG and Corporate Communications Cheryl Blanchard - President & CEO Mike Levitz - EVP & CFO Conference Call Participants George Sellers - Stephens Jim Sidoti - Sidoti & Company Mike Petusky - Barrington Research Operator Greetings, and welcome to Anika's Fourth Quarter and Year-End 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode ...

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2022 Results Conference Call November 8, 2022 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Dr. Cheryl Blanchard - President and Chief Executive Officer Mike Levitz - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants George Sellers - Stephens Incorporated Mike Petusky - Barrington Research Jim Sidoti - Sidoti & Company Operator Good evening, ladies and g ...

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michael Levitz - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants James Sidoti - Sidoti & Company Michael Petusky - Barrington Research Operator Good evening, ladies and gentlemen, and welcome to Anika's Sec ...

Financial Performance - Total revenue increased by 4% to $39.7 million[29] - OA Pain Management revenue increased by 6% to $25.7 million[29] - Joint Preservation and Restoration revenue increased by 2% to $12.1 million[29] - Non-Orthopedic revenue decreased by 6% to $1.8 million[29] - Gross margin was 63%, including $1.6 million of non-cash acquisition-related expenses; adjusted gross margin was 67%[29] - Net loss was ($2.8) million, or ($0.20) per share; adjusted net loss was ($1.6) million, or ($0.12) per share[29] - Adjusted EBITDA was $4.4 million[29] - Cash balance as of June 30, 2022, was $91.4 million[29] Business Highlights - Received 510(k) clearance for X-Twist™ fixation system, with limited market release planned for 2H 2022[5] - Continuing to ramp up Joint Preservation medical education activities, with 270 surgeons trained YTD[5] - Tactoset® received an ACE award for innovation at the American Orthopaedic Society for Sports Medicine (AOSSM) meeting[5] - Completed last patient follow-up in Cingal® pilot study, with data read-out planned for Fall 2022[5]

Financial Data and Key Metrics Changes - Total revenue for Q1 2022 was $36.7 million, an increase of 7% compared to the prior year [21] - Gross margin was 59%, with an adjusted gross margin of 64% after excluding noncash acquisition-related expenses [22] - Net loss for the quarter was $2.9 million, or $0.20 per share, compared to net income of $2.8 million, or $0.20 per diluted share in Q1 2021 [23] - Adjusted EBITDA was $2.6 million, down from $4.8 million in the same quarter last year [24] Business Line Data and Key Metrics Changes - OA pain management revenue increased by 18% to $22.7 million, driven by favorable order timing [21] - Joint preservation and restoration revenue decreased by 1% from $12.2 million to $12.1 million, showing some recovery after early quarter COVID headwinds [22] - Nonorthopedic revenue was $1.8 million, down 34% from the previous year due to higher revenues from last time buys of legacy products [22] Market Data and Key Metrics Changes - The company noted that the macroeconomic effects of staffing shortages and supply chain issues could remain as headwinds for the industry [10] - The healthcare environment appears to be improving, which is expected to positively impact market conditions [42] Company Strategy and Development Direction - The company is focused on becoming a leading provider of early intervention and joint preservation solutions, with several new product launches planned in the shoulder and foot and ankle spaces within the next six to 24 months [14][20] - The addition of Rob Delp as Vice President of U.S. Sales is expected to enhance commercial strategy execution [13] - The company aims for mid-teens revenue growth and an adjusted gross margin of 70% over the long term, despite being behind its original five-year target due to COVID impacts [28] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for market improvement through the year as COVID-related impacts abate [10] - The company reiterated its full-year 2022 total revenue outlook of low to mid-single-digit percentage growth over 2021, with expectations for joint preservation and restoration to be the fastest-growing product family [25][26] - Adjusted EBITDA margin is expected to be in the low to mid-single digits due to targeted spending investments and ongoing supply chain challenges [28] Other Important Information - The company has ramped up medical education efforts, training over 140 surgeons to date [11] - The company is investing in commercial capabilities and product development to support growth objectives [27] Q&A Session Summary Question: Inquiry about OA pain management growth assumptions - Management indicated that the OA pain management market is expected to grow at about 1%, with the company aiming to grow ahead of the market [33] Question: Update on CINGAL pilot trial timeline - Management confirmed that data readout for the CINGAL pilot trial is expected in the fall, with updates to be provided at that time [36] Question: Clarification on OA pain management business strength - Management noted that the strong performance was due to favorable timing in international markets and veterinary products, but they did not change their full-year guidance [38] Question: Joint preservation revenue decline and future expectations - Management acknowledged a tough January due to Omicron but expects recovery and growth catalysts to drive improvement in the coming quarters [41]